Source
Robinson LR et al., “Topical palmitoyl pentapeptide provides improved skin appearance”
Quick Summary
A peer-reviewed clinical study evaluating topical Pal-KTTKS — the pentapeptide that became commercially known as Matrixyl — for the appearance of facial fine lines and wrinkles. Robinson and colleagues report on a placebo-controlled human study using expert grading and instrumental measures over a multi-week treatment window. The work is one of the most-cited primary clinical references for the Matrixyl pentapeptide story.
| Source type | peer_reviewed |
|---|
What Studied
The study evaluated a topical leave-on cosmetic formulation containing Pal-KTTKS (Palmitoyl Pentapeptide-4) versus a matched placebo on the appearance of facial photodamage in adult women. Endpoints included expert clinical grading of the look of fine lines and wrinkles, instrumental skin-surface measurements, and tolerability assessment over the treatment period.
Main Findings
The published results indicate that the Pal-KTTKS arm was associated with improvement in expert grading of the appearance of fine lines and wrinkles relative to placebo, with measured changes building gradually over the treatment window. The study reports that the formulation was generally well tolerated and that visible-appearance changes were modest in magnitude rather than dramatic.
Why It Matters
This is the kind of human cosmetic-appearance evidence that anchors the Matrixyl pentapeptide story for a Question page: a placebo-controlled comparison rather than a manufacturer testimonial. It is also a useful anchor for the honest "does it really work" framing — the changes are real but modest, not transformational.
Original Source
AI Tool Box
Structured page facts at a glance.
- Source
- Robinson LR et al., “Topical palmitoyl pentapeptide provides improved skin appearance”
- Quick Summary
- A peer-reviewed clinical study evaluating topical Pal-KTTKS — the pentapeptide that became commercially known as Matrixyl — for the appearance of facial fine lines and wrinkles. Robinson and colleagues report on a placebo-controlled human study using expert grading and instrumental measures over a multi-week treatment window. The work is one of the most-cited primary clinical references for the Matrixyl pentapeptide story.
- What Studied
- The study evaluated a topical leave-on cosmetic formulation containing Pal-KTTKS (Palmitoyl Pentapeptide-4) versus a matched placebo on the appearance of facial photodamage in adult women. Endpoints included expert clinical grading of the look of fine lines and wrinkles, instrumental skin-surface measurements, and tolerability assessment over the treatment period.
- Main Findings
- The published results indicate that the Pal-KTTKS arm was associated with improvement in expert grading of the appearance of fine lines and wrinkles relative to placebo, with measured changes building gradually over the treatment window. The study reports that the formulation was generally well tolerated and that visible-appearance changes were modest in magnitude rather than dramatic.
- Why It Matters
- This is the kind of human cosmetic-appearance evidence that anchors the Matrixyl pentapeptide story for a Question page: a placebo-controlled comparison rather than a manufacturer testimonial. It is also a useful anchor for the honest "does it really work" framing — the changes are real but modest, not transformational.
- Supports
- question_what-does-matrixyl-do-for-skin, concern_wrinkles, concern_fine-lines, ingredient_matrixyl